drugset
drugset / Trial / NCT04331613

Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS

NCT04331613 ↗

Phase 1/2 Unknown 9 enrolled Chinese Academy of Sciences Beijing YouAn Hospital · collab
NaSingle-groupOpen-labelTreatment

Summary

A phase1/2, open label, dose escalation, safety and early efficacy study of CAStem for the treatment of severe COVID-19 associated with or without ARDS.

Timeline

Start
2020-01-27
Primary completion
2020-12
Completion
2020-12

Drugs

EvaluationDrugModalityDoseRoute
Subject CAStem Cell therapy 3e+06 cells/kg Intravenous
Subject CAStem Cell therapy 5e+06 cells/kg Intravenous
Subject CAStem Cell therapy 1e+07 cells/kg Intravenous

Indications

COVID-19 acute lung injury acute respiratory distress syndrome viral pneumonia